Tsumura & Co
TSE:4540

Watchlist Manager
Tsumura & Co Logo
Tsumura & Co
TSE:4540
Watchlist
Price: 3 355 JPY -1.7% Market Closed
Market Cap: 257.5B JPY

Net Margin
Tsumura & Co

17.9%
Current
14%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.9%
=
Net Income
32.4B
/
Revenue
181.1B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
JP
Tsumura & Co
TSE:4540
254.1B JPY
18%
US
Eli Lilly and Co
NYSE:LLY
700.7B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
372.4B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
35%
CH
Roche Holding AG
SIX:ROG
210.7B CHF
14%
CH
Novartis AG
SIX:NOVN
185.7B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
164B GBP
14%
US
Merck & Co Inc
NYSE:MRK
190.2B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
132.8B USD
13%

Tsumura & Co
Glance View

Market Cap
254.1B JPY
Industry
Pharmaceuticals

Tsumura & Co., a venerable name in the herbal medicine industry, traces its roots back to 1893. Emerging from Japan's rich pharmacopeia tradition, the company has carved a niche by blending age-old herbal knowledge with contemporary research and quality control. This synergy allows Tsumura to thrive in the modern marketplace, offering Kampo—a traditional Japanese herbal medicine—as their primary product line. Tsumura stands out in its meticulous approach to sourcing high-quality raw materials, employing state-of-the-art technology to ensure efficacy and safety. This rigorous quality assurance not only honors the integrity of traditional formulas but also aligns with the stringent standards of modern healthcare. In its pursuit of growth, Tsumura expertly navigates the delicate balance between tradition and innovation. The company generates revenue through the sale of its Kampo products, which are widely used in clinics and hospitals across Japan, reflecting a significant integration into the mainstream healthcare system. Additionally, Tsumura's strategic collaborations with pharmaceutical companies expand its reach into international markets. Through educational initiatives, they further advocate for the understanding and acceptance of herbal medicine globally. By continually investing in research and development, Tsumura aims to bolster their product offerings, ensuring that the ancient wisdom of Kampo remains relevant in today's fast-paced, health-conscious world.

Intrinsic Value
5 760.03 JPY
Undervaluation 42%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
17.9%
=
Net Income
32.4B
/
Revenue
181.1B
What is the Net Margin of Tsumura & Co?

Based on Tsumura & Co's most recent financial statements, the company has Net Margin of 17.9%.

Back to Top